Table 3 Metastasis-free survival univariate analyses (parametric and 1000-permutation tests)

From: Validation of UBE2C protein as a prognostic marker in node-positive breast cancer

Variable

HR

HR 95% CI

Parametric P -value

1000-permutation P -value

Age

1.08

1.03–1.13

0.001

<0.001

Histology

    

 IDC vs others

0.58

0.24–1.39

0.219

0.265

Histological size

    

 Raw value

1.03

1.01–1.05

0.035

0.063

 ⩾20 mm vs <20 mm

1.92

0.66–5.59

0.233

0.194

SBR

    

 I vs II vs III

3.15

1.59–6.23

0.001

<0.001

SBR

    

 I, II vs III

3.94

1.72–9.01

0.001

<0.001

 N° positive nodes

1.28

1.17–1.40

<0.001

<0.001

Positive nodes

    

 1 vs 2 vs 3 vs > 3

2.02

1.39–2.94

<0.001

<0.001

Positive nodes

    

 <3 vs ⩾3

5.17

2.30–11.64

<0.001

<0.001

ER

    

 + vs −

0.21

0.09–0.49

<0.001

0.001

PR

    

 + vs −

0.42

0.19–0.94

0.035

0.043

Hormonotherapy

    

 + vs −

0.39

0.17–0.91

0.029

0.042

IHC Ki-67 raw value

1.02

1.01–1.04

0.011

0.012

IHC Ki-67

    

 <11% vs ⩾11%

5.69

1.34–24.2

0.018

0.002

IHC UBE2C raw value

1.03

1.01–1.04

0.001

<0.001

IHC UBE2C

    

 <11% vs ⩾11%

6.79

2.03–22.73

0.002

<0.001

NPI raw value

2.81

1.84–4.28

<0.001

<0.001

NPI score

    

 1 vs 2 vs 3

5.45

2.33–12.71

<0.001

<0.001

NPI

    

 1, 2 vs 3

5.85

2.44–14.04

<0.001

<0.001

  1. CI=confidence interval; ER=oestrogen receptor; HR=hazard ratio; IDC=infiltrating ductal carcinoma; IHC=immunohistochemistry; NPI=Nottingham prognostic index; PR=progesterone receptor; SBR=Scarff–Bloom–Richardson.
Back to article page